Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CXCR1 Biologics Sequence Review Report 2026: C-X-C chemokine receptor type 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CXCR1 Biologics Sequence Review Report 2026: C-X-C chemokine receptor type 1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CXCR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IL32 Biologics Sequence Review Report 2026: Interleukin-32 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IL32 Biologics Sequence Review Report 2026: Interleukin-32 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of IL32 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD19 Biologics Sequence Review Report 2026: B-lymphocyte antigen CD19 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD19 Biologics Sequence Review Report 2026: B-lymphocyte antigen CD19 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD19 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGA4 Biologics Sequence Review Report 2026: Integrin alpha-4 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGA4 Biologics Sequence Review Report 2026: Integrin alpha-4 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGA4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGAM Biologics Sequence Review Report 2026: Integrin alpha-M Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGAM Biologics Sequence Review Report 2026: Integrin alpha-M Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGAM protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FGF7 Biologics Sequence Review Report 2026: Fibroblast growth factor 7 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FGF7 Biologics Sequence Review Report 2026: Fibroblast growth factor 7 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FGF7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IL11 Biologics Sequence Review Report 2026: Interleukin-11 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IL11 Biologics Sequence Review Report 2026: Interleukin-11 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of IL11 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CXCL3 Biologics Sequence Review Report 2026: C-X-C motif chemokine 3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CXCL3 Biologics Sequence Review Report 2026: C-X-C motif chemokine 3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CXCL3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CXCL2 Biologics Sequence Review Report 2026: C-X-C motif chemokine 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CXCL2 Biologics Sequence Review Report 2026: C-X-C motif chemokine 2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CXCL2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IL1RN Biologics Sequence Review Report 2026: Interleukin-1 receptor antagonist protein Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IL1RN Biologics Sequence Review Report 2026: Interleukin-1 receptor antagonist protein Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of IL1RN protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD7 Biologics Sequence Review Report 2026: T-cell antigen CD7 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD7 Biologics Sequence Review Report 2026: T-cell antigen CD7 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD48 Biologics Sequence Review Report 2026: CD48 antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD48 Biologics Sequence Review Report 2026: CD48 antigen Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD48 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →